Open Collections

UBC Faculty Research and Publications

Lipid Lowering Therapy Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 24 is based primarily on 2 published meta-analyses and an in-house systematic review and critical appraisal of the large double-blind randomized controlled trials (RCTs) examining the impacts of lipid lowering therapy. Conclusions: Lipid lowering dietary therapy can be effective and should be a component of all treatment regimens. In secondary prevention, in men age 35 to 70, the benefits from using statins are clear. The absolute benefits are greater the higher the cholesterol. Treatment with niacin is also effective, but is associated with a significant increase in problematic side effects. More secondary prevention data are needed for women and for all patients older than 70 years to be confident that the absolute benefit is the same in these groups. Primary prevention with lipid lowering therapy in high risk men age 45 to 64 causes a statistically significant reduction in MI and/or CV death, however large numbers of patients have to be treated for 5 years to prevent one event. Data are lacking for primary prevention for women and for all patients over age 65.

Item Metadata

Title
Lipid Lowering Therapy
Alternate Title
Therapeutics Letter 24
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
1998-05
Description
Therapeutics Letter 24 is based primarily on 2 published meta-analyses and an in-house systematic review and critical appraisal of the large double-blind randomized controlled trials (RCTs) examining the impacts of lipid lowering therapy. Conclusions: Lipid lowering dietary therapy can be effective and should be a component of all treatment regimens. In secondary prevention, in men age 35 to 70, the benefits from using statins are clear. The absolute benefits are greater the higher the cholesterol. Treatment with niacin is also effective, but is associated with a significant increase in problematic side effects. More secondary prevention data are needed for women and for all patients older than 70 years to be confident that the absolute benefit is the same in these groups. Primary prevention with lipid lowering therapy in high risk men age 45 to 64 causes a statistically significant reduction in MI and/or CV death, however large numbers of patients have to be treated for 5 years to prevent one event. Data are lacking for primary prevention for women and for all patients over age 65.
Subject
Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Secondary Prevention
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433603
URI
http://hdl.handle.net/2429/85013
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International